Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Mar;41(3):587–593. doi: 10.1128/aac.41.3.587

Activities of various compounds against murine and primate polyomaviruses.

G Andrei 1, R Snoeck 1, M Vandeputte 1, E De Clercq 1
PMCID: PMC163756  PMID: 9055998

Abstract

Polyomavirus infections in humans are due to BK virus (BKV) and JC virus (JCV). Diseases associated with human polyomaviruses occur mostly in immunocompromised adults, e.g., progressive multifocal leukoencephalopathy (PML), caused by JCV, in AIDS patients and hemorrhagic cystitis and uretral stenosis, caused by BKV, in transplant recipients. No therapy is available for these diseases, which necessitates the development of chemical entities that are active against polyomaviruses. Several antiviral compounds were evaluated to determine their effects on the in vitro replication of mouse polyomavirus and the primate viruses simian virus 40 (SV40), SV40 PML-1, and SV40 PML-2. The activity of the different compounds was assessed by a cytopathic effect reduction assay and confirmed in a virus yield assay. Cidofovir [HPMPC; (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine] and its cyclic counterpart emerged as the most selective antipolyomavirus agents. The 50% inhibitory concentrations for HPMPC were in the range of 4 to 7 micrograms/ml, and its selectivity index varied from 11 to 20 for mouse polyomavirus and from 23 to 33 for SV40 strains in confluent cell monolayers. Cell cytotoxicity was up to 15-fold greater in growing cells. Other acyclic nucleoside phosphonates (i.e., HPMPA; [(S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine] and PMEG [9-(2-phosphonylmethoxyethyl)-guanine]) also showed some activity but had low selectivity. None of the other drugs tested against these animal viruses (i.e., acyclovir, ganciclovir, brivudine, ribavirin, foscarnet, and cytarabine) showed significant activity. Thus, HPMPC deserves further evaluation as a candidate drug for polyomavirus infections in the immunocompromised host.

Full Text

The Full Text of this article is available as a PDF (233.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antinori A., De Luca A., Ammassari A., Cingolani A., Murri R., Colosimo G., Roselli R., Scerrati M., Tamburrini E. Failure of cytarabine and increased JC virus-DNA burden in the cerebrospinal fluid of patients with AIDS-related progressive multifocal leucoencephalopathy. AIDS. 1994 Jul;8(7):1022–1024. [PubMed] [Google Scholar]
  2. Arthur R. R., Beckmann A. M., Li C. C., Saral R., Shah K. V. Direct detection of the human papovavirus BK in urine of bone marrow transplant recipients: comparison of DNA hybridization with ELISA. J Med Virol. 1985 May;16(1):29–36. doi: 10.1002/jmv.1890160105. [DOI] [PubMed] [Google Scholar]
  3. Arthur R. R., Shah K. V. Occurrence and significance of papovaviruses BK and JC in the urine. Prog Med Virol. 1989;36:42–61. [PubMed] [Google Scholar]
  4. Berger J. R., Kaszovitz B., Post M. J., Dickinson G. Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases. Ann Intern Med. 1987 Jul;107(1):78–87. doi: 10.7326/0003-4819-107-1-78. [DOI] [PubMed] [Google Scholar]
  5. Corallini A., Pagnani M., Viadana P., Silini E., Mottes M., Milanesi G., Gerna G., Vettor R., Trapella G., Silvani V. Association of BK virus with human brain tumors and tumors of pancreatic islets. Int J Cancer. 1987 Jan 15;39(1):60–67. doi: 10.1002/ijc.2910390111. [DOI] [PubMed] [Google Scholar]
  6. De Clercq E., Sakuma T., Baba M., Pauwels R., Balzarini J., Rosenberg I., Holý A. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res. 1987 Dec;8(5-6):261–272. doi: 10.1016/s0166-3542(87)80004-9. [DOI] [PubMed] [Google Scholar]
  7. Dörries K., Loeber G., Meixensberger J. Association of polyomaviruses JC, SV40, and BK with human brain tumors. Virology. 1987 Sep;160(1):268–270. doi: 10.1016/0042-6822(87)90071-7. [DOI] [PubMed] [Google Scholar]
  8. Fong I. W., Toma E. The natural history of progressive multifocal leukoencephalopathy in patients with AIDS. Canadian PML Study Group. Clin Infect Dis. 1995 May;20(5):1305–1310. doi: 10.1093/clinids/20.5.1305. [DOI] [PubMed] [Google Scholar]
  9. Gardner S. D., MacKenzie E. F., Smith C., Porter A. A. Prospective study of the human polyomaviruses BK and JC and cytomegalovirus in renal transplant recipients. J Clin Pathol. 1984 May;37(5):578–586. doi: 10.1136/jcp.37.5.578. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Guarino M., D'Alessandro R., Rinaldi R., Stracciari A., Pazzaglia P., Costigliola P., Marinacci G., Chiodo F., Di Giandomenico G., Cancellieri C. Progressive multifocal leucoencephalopathy in AIDS: treatment with cytosine arabinoside. AIDS. 1995 Jul;9(7):819–820. [PubMed] [Google Scholar]
  11. Major E. O., Amemiya K., Tornatore C. S., Houff S. A., Berger J. R. Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev. 1992 Jan;5(1):49–73. doi: 10.1128/cmr.5.1.49. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Major E. O., Ault G. S. Progressive multifocal leukoencephalopathy: clinical and laboratory observations on a viral induced demyelinating disease in the immunodeficient patient. Curr Opin Neurol. 1995 Jun;8(3):184–190. [PubMed] [Google Scholar]
  13. Major E. O., Vacante D. A. Human fetal astrocytes in culture support the growth of the neurotropic human polyomavirus, JCV. J Neuropathol Exp Neurol. 1989 Jul;48(4):425–436. doi: 10.1097/00005072-198907000-00004. [DOI] [PubMed] [Google Scholar]
  14. Markowitz R. B., Thompson H. C., Mueller J. F., Cohen J. A., Dynan W. S. Incidence of BK virus and JC virus viruria in human immunodeficiency virus-infected and -uninfected subjects. J Infect Dis. 1993 Jan;167(1):13–20. doi: 10.1093/infdis/167.1.13. [DOI] [PubMed] [Google Scholar]
  15. Marshall W. F., Telenti A., Proper J., Aksamit A. J., Smith T. F. Survey of urine from transplant recipients for polyomaviruses JC and BK using the polymerase chain reaction. Mol Cell Probes. 1991 Apr;5(2):125–128. doi: 10.1016/0890-8508(91)90006-6. [DOI] [PubMed] [Google Scholar]
  16. Portegies P., Algra P. R., Hollak C. E., Prins J. M., Reiss P., Valk J., Lange J. M. Response to cytarabine in progressive multifocal leucoencephalopathy in AIDS. Lancet. 1991 Mar 16;337(8742):680–681. doi: 10.1016/0140-6736(91)92504-u. [DOI] [PubMed] [Google Scholar]
  17. Simpson D. M., Tagliati M. Neurologic manifestations of HIV infection. Ann Intern Med. 1994 Nov 15;121(10):769–785. doi: 10.7326/0003-4819-121-10-199411150-00008. [DOI] [PubMed] [Google Scholar]
  18. Snoeck R., Van Ranst M., Andrei G., De Clercq E., De Wit S., Poncin M., Clumeck N. Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue. N Engl J Med. 1995 Oct 5;333(14):943–944. doi: 10.1056/NEJM199510053331418. [DOI] [PubMed] [Google Scholar]
  19. Steiger M. J., Tarnesby G., Gabe S., McLaughlin J., Schapira A. H. Successful outcome of progressive multifocal leukoencephalopathy with cytarabine and interferon. Ann Neurol. 1993 Apr;33(4):407–411. doi: 10.1002/ana.410330415. [DOI] [PubMed] [Google Scholar]
  20. Van Cutsem E., Snoeck R., Van Ranst M., Fiten P., Opdenakker G., Geboes K., Janssens J., Rutgeerts P., Vantrappen G., de Clercq E. Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine. J Med Virol. 1995 Feb;45(2):230–235. doi: 10.1002/jmv.1890450221. [DOI] [PubMed] [Google Scholar]
  21. Wiley C. A., Grafe M., Kennedy C., Nelson J. A. Human immunodeficiency virus (HIV) and JC virus in acquired immune deficiency syndrome (AIDS) patients with progressive multifocal leukoencephalopathy. Acta Neuropathol. 1988;76(4):338–346. doi: 10.1007/BF00686970. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES